Promoter methylation and large intragenic rearrangements of <it>DPYD </it>are not implicated in severe toxicity to 5-fluorouracil-based chemotherapy in gastrointestinal cancer patients
<p>Abstract</p> <p>Background</p> <p>Severe toxicity to 5-fluorouracil (5-FU) based chemotherapy in gastrointestinal cancer has been associated with constitutional genetic alterations of the dihydropyrimidine dehydrogenase gene (<it>DPYD</it>).</p> <...
Main Authors: | Savva-Bordalo Joana, Ramalho-Carvalho João, Pinheiro Manuela, Costa Vera L, Rodrigues Ângelo, Dias Paula C, Veiga Isabel, Machado Manuela, Teixeira Manuel R, Henrique Rui, Jerónimo Carmen |
---|---|
Format: | Article |
Language: | English |
Published: |
BMC
2010-09-01
|
Series: | BMC Cancer |
Online Access: | http://www.biomedcentral.com/1471-2407/10/470 |
Similar Items
-
Hypermethylation of the DPYD promoter region is not a major predictor of severe toxicity in 5-fluorouracil based chemotherapy
by: Aebi Stefan, et al.
Published: (2008-10-01) -
<i>DPYD</i> and Fluorouracil-Based Chemotherapy: Mini Review and Case Report
by: Theodore J. Wigle, et al.
Published: (2019-05-01) -
A novel large intragenic DPYD deletion causing dihydropyrimidine dehydrogenase deficiency: a case report
by: Anna Malekkou, et al.
Published: (2024-03-01) -
Intragenic β-synuclein rearrangements in malignancy
by: Peifang Xiao, et al.
Published: (2023-05-01) -
Importance of Rare DPYD Genetic Polymorphisms for 5-Fluorouracil Therapy in the Japanese Population
by: Eiji Hishinuma, et al.
Published: (2022-06-01)